Home / ACCCBuzz Blog / Full Story

ACCC Submits Comments to FDA on Draft Guidance to Increase Diversity in Clinical Trials


June 13, 2022

The ACCC Community Oncology Research Institute (ACORI) Task Force submitted comments to the Food and Drug Administration (FDA) in response to the agency's draft guidance on Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.
Read the Letter


«« Previous
ACCC Urges Congress to Address Access to Coverage and Cancer Care Affordability
Next »»
ACCC Asks Senate Leaders to Include Clinical Trial Diversity Provisions in PDUFA Reauthorization

Categories

We welcome you to share our blog content. We want to connect people with the information they need. We just ask that you link back to the original post and refrain from editing the text. Any questions? Email Chidi Ike, Content Manager.

To receive a weekly digest of ACCCBuzz blog posts each Friday, please sign up in the box to the left.

 

More Blog Posts

Related Content